MARKET

NKTX

NKTX

Nkarta, Inc.
NASDAQ
3.380
+0.080
+2.42%
After Hours: 3.301 -0.079 -2.33% 17:14 07/07 EDT
OPEN
3.320
PREV CLOSE
3.300
HIGH
3.590
LOW
3.220
VOLUME
1.17M
TURNOVER
--
52 WEEK HIGH
3.650
52 WEEK LOW
1.680
MARKET CAP
241.82M
P/E (TTM)
-2.5057
1D
5D
1M
3M
1Y
5Y
1D
Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth
Simply Wall St · 11h ago
Weekly Report: what happened at NKTX last week (0629-0703)?
Weekly Report · 1d ago
Weekly Report: what happened at NKTX last week (0622-0626)?
Weekly Report · 06/29 10:17
Nkarta joins H.C. Wainwright Cell Therapy Virtual Conference fireside chat
PUBT · 06/26 12:45
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Barchart · 06/26 07:45
Nkarta initiated with a Buy at TD Cowen
TipRanks · 06/23 11:33
Phil Nadeau Reiterates Buy on Nkarta, Citing Differentiated NK Cell Platform and CD19 CAR NK Therapy as Key Long-Term Value Drivers
TipRanks · 06/23 09:55
NKARTA INC <NKTX.O>: TD COWEN INITIATES COVERAGE WITH BUY RATING
Reuters · 06/23 09:45
More
About NKTX
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.

Webull offers Nkarta Inc stock information, including NASDAQ: NKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTX stock methods without spending real money on the virtual paper trading platform.